The main burden of CS/PHTS is the increased risk of malignancy, conceivably due to PTEN inactivation/mutation, so that an early diagnosis is of paramount importance in order to enter tailored surveillance programs. Here, PTEN is linked to PTEN hamartoma tumor syndrome.